The ACADIA Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $19.20 and its highest was $57.46 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.44B.
What is ACADIA Pharmaceuticals’s price target?
The average price target for ACADIA Pharmaceuticals is $26.70. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $32.00 ,the lowest forecast is $18.00. The average price target represents 24.42% Increase from the current price of $21.46.
What do analysts say about ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Aug 04, 2021 which is in 10 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on May 05, 2021. The company reported -$0.415 earnings per share for the quarter, beating the consensus estimate of -$0.53 by $0.115.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 160,180,000 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of -$0.415 in its last earnings report, beating expectations of -$0.53. Following the earnings report the stock price went up 7.326%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Perceptive Advisors LLC. It holds ACADIA Pharmaceuticals’s shares valued at 36M.